AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own MKS today, you generally have to believe in its role supplying core technologies to semiconductor and advanced packaging customers, despite cyclical and leverage risks. The new proposal on special shareholder meetings is a governance issue, and on its own does not appear to change the near term earnings catalysts or the key risks around debt, tariffs, and chip cycle volatility in a material way.
The recent refinancing of €1.0 billion of senior notes, with expected annual cash interest savings of about US$27 million, is more directly tied to those core risks and catalysts. It speaks to MKS’s effort to manage its high leverage and interest burden, which many investors see as central to the story alongside demand for AI and advanced packaging.
Yet beneath the governance headlines, you should be aware that concentrated leverage and interest coverage remain a key risk that could...
Read the full narrative on MKS (it's free!)
MKS' narrative projects $4.4 billion revenue and $475.8 million earnings by 2028.
Uncover how MKS' forecasts yield a $180.92 fair value, a 21% downside to its current price.
Some of the lowest analysts see much tougher conditions ahead, even while assuming revenue of about US$5.0 billion and earnings near US$684 million by 2029, so this activism and governance friction could prompt meaningful updates to both the more optimistic and the more cautious stories you use to judge MKS.
Explore 4 other fair value estimates on MKS - why the stock might be worth as much as 39% more than the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Every day counts. These free picks are already gaining attention. See them before the crowd does:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com